Application Deadline
March 31, 2021

Senior Manager for Product Development

Position Summary

The Senior Manager for Product Development will be responsible for working with the team to meet MultiplexDX timelines and objectives and will coordinate the development and production teams. Senior Manager for Product Development will report directly to the Company Management. The applicant must demonstrate strong leadership, experience, and scientific skills to drive team performance and meet challenging goals in the product development process. It is mandatory to demonstrate the experience of the development of at least one CE IVD certified product.

Minimum Education, Experience and Skills

  • PhD or Masters in Biology, Molecular Biology, Biochemistry, or Pharmaceutical Science related degree
  • Experience in developing IVD certified product
  • Experienced team leader
  • Strong molecular biology background (immunoassay, PCR/RT-PCR development and troubleshooting)
  • Solid understanding of European and US IVD regulations including application in a laboratory environment
  • Previous experience working with regulatory body (SUKL/EMA/FDA) and participating in regulatory agency inspections is of particular advantage
  • Ability to successfully solve challenging issues, critical thinking and detail oriented
  • Strong interpersonal, verbal and written communication skills
  • Ability to work well in a fast-paced, goal-oriented environment
  • Excellent organizational ability – can easily multi-task and shift priorities as needed
  • Ability to work independently
  • Ability to tailor communications to all levels in the organization and prepare appropriate updates to functional groups

For additional information, please contact

Peter Kilian
Ilkovičova 8
84104 Bratislava, Slovakia

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter